Sign In
Buy TBPH
$15.92
+0.340 (+2.18%)
At Close: Jun 03, 2026
TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study
11:35am, Wednesday, 04'th Mar 2026
Theravance Biopharma shares plummet 26% after its phase III CYPRESS study of ampreloxetine missed key endpoints, prompting the company to halt the program.
Theravance Biopharma Plummets As Phase 3 Study Falls Short
01:19pm, Tuesday, 03'rd Mar 2026
Theravance Biopharma Inc. (NASDAQ: TBPH) shares are tumbling on Tuesday following the company's Phase 3 CYPRESS study did not meet its primary endpoint.
The Excruciating Failure That Could Cause Theravance, Down 27%, To Sell Itself
12:14pm, Tuesday, 03'rd Mar 2026
Theravance Biopharma said it could be for sale Tuesday after its Phase 3 effort to treat a rare disease flopped. The biotech stock crashed.
Theravance Biopharma shares plunge 26% after drug trial failure triggers strategic review
11:08am, Tuesday, 03'rd Mar 2026
The company is working with Lazard on a potential sale after its lead drug candidate disappointed in a late-stage study Theravance Biopharma shares collapsed 26% in morning trading on Tuesday after th
Theravance plans strategic review, including possible sale, after drug trial failure
08:45am, Tuesday, 03'rd Mar 2026
Theravance Biopharma said on Tuesday it is initiating a strategic review, including a possible sale of the company, after its experimental drug to treat a type of blood pressure disorder f
Phase 3 CYPRESS study did not meet the primary endpoint , the OHSA Composite Score, a patient reported outcome (PRO) Cash of $326.5 million at Q4 2025 (no debt); approximately $400 million expected at
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet?
09:06am, Tuesday, 24'th Feb 2026
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
Hillsdale Investment Management Inc. Purchases New Position in Theravance Biopharma, Inc. $TBPH
05:39am, Monday, 23'rd Feb 2026
Hillsdale Investment Management Inc. acquired a new stake in Theravance Biopharma, Inc. (NASDAQ: TBPH) in the undefined quarter, according to the company in its most recent 13F filing with the Securit
Financial Survey: Amylyx Pharmaceuticals (NASDAQ:AMLX) vs. Theravance Biopharma (NASDAQ:TBPH)
01:15am, Tuesday, 10'th Feb 2026
Theravance Biopharma (NASDAQ: TBPH - Get Free Report) and Amylyx Pharmaceuticals (NASDAQ: AMLX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will comp
Is the Options Market Predicting a Spike in Theravance Biopharma Stock?
02:16pm, Wednesday, 28'th Jan 2026
Investors need to pay close attention to TBPH stock based on the movements in the options market lately.
Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term
10:51am, Friday, 23'rd Jan 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term
10:45am, Thursday, 15'th Jan 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term
10:50am, Tuesday, 06'th Jan 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Theravance Biopharma (TBPH) is a Strong Growth Stock
10:46am, Wednesday, 24'th Dec 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Wall Street Analysts Believe Theravance Bio (TBPH) Could Rally 42.15%: Here's is How to Trade
10:56am, Monday, 22'nd Dec 2025
The mean of analysts' price targets for Theravance Bio (TBPH) points to a 42.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a
